Slide 1: First Quarter 2023 Operating & Financial Results Conference Call / Webinar
First Quarter 2023 Operating & Financial Results Conference Call / Webinar May 9th, 2023 4:30 PM Eastern Time NASDAQ :LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Contents Speakers Host
Contents Speakers Host 01 Introduction 02 Q1 2023 Highlights Panna Sharma Chief Executive Officer, President and Director 03 RADR® Highlights 04 Scientific Highlights Nicole Leber 05 Financial Highlights David Margrave Investor Relations Chief Financial Officer 06 Q&A 2
Slide 4: Using AI, Lantern is Transforming Drug Discovery Timelines and Cost
Using AI, Lantern is Transforming Drug Discovery Timelines and Cost Lantern has launched 9 programs in two years, and is anticipating launching Multiple Phase 1 trials in 2023 Lantern’s Drug Development Model Large Scale/Multi-omics Proprietary AI Accelerated timeline Oncology Data platform RADR® an
Slide 5: Lantern's Diverse & Unique AI Driven Pipeline of Drug Programs
Lantern’s Diverse & Unique AI Driven Pipeline of Drug Programs Lantern has 14 disclosed and collaborative drug programs including the Phase 2 Harmonic™ trial Program Indication Discovery Optimization Preclinical Pre IND Phase I Phase II LP-300 Non-Small Cell Lung Cancer (NSCLC) LP-100 Homologous Rep
Slide 6: First Quarter 2023 Highlights
First Quarter 2023 Highlights RADR® AI Platform Updates LP-184 for Solid Tumors • Developed industry-leading AI algorithms to predict any • Filing of the IND application anticipated in early May compound’s BBB permeability • Phase 1 clinical trial anticipated in mid-2023 • Breakthrough AI algorithms
Slide 7: RADR is Lantern's AI and Machine-Learning Platform
RADR® is Lantern’s AI and Machine-Learning Platform that Powers Oncology Drug Discovery and Development Response Algorithm for Drug Positioning & Rescue A proprietary integrated data analytics, experimental biology, oncology-focused, machine-learning-based platform focused on drug development 80%+ R
Slide 8: RADR Solves Predicting Any Compound's Blood Brain Barrier Permeability
RADR® Solves one of the Most Challenging Problems in Brain Cancer Drug Discovery – Predicting any Compound’s Blood Brain Barrier Permeability What is the Blood-Brain-Barrier (BBB)? Blood-brain-barrier (BBB) is a highly selective border that can prevent drugs from entering brain tissues. The BBB prev
Slide 9: RADR's Library of Over 200+ Advanced Algorithms
RADR®’s Library of Over 200+ Advanced Algorithms Powers its Drug Development Capabilities Example RADR® Algorithms Ensemble Deep Learning Bayesian Based Tree Based Rule Based Clustering Others Examples Regression • Predicting drug sensitivity values, e.g. IC50 Supervised Learning • Predicting blood
Slide 10: ADCs are one of the Fastest Growing Drug Segments
ADCs are one of the Fastest Growing Drug Segments and can be Developed Faster and More Effectively with AI What are Antibody Drug Conjugates (ADCs)? Rapidly growing global ADC market Antibody drug conjugates (ADCs) are highly specific cancer-targeted antibodies linked to potent anti-tumor small molec
Slide 11: The Harmonic Trial for Never Smoker Patients with NSCLC
The Harmonic™ Trial for Never Smoker Patients with NSCLC Major Updates Additional Value Drivers • First patient dosed in March 2023 Harmonic™ iPhone App • Activated 5 sites across 12 different locations in the US: First of their kind iPhone apps launched for the • Gabrail Cancer Center Harmonic™ cli
Slide 12: LP-184 has Blockbuster Potential Across Multiple Cancers
LP-184 has Blockbuster Potential Across Multiple Cancers as a Single Agent or in Combination Therapy Solid Tumors $6-7 billion Program Highlights DDR Deficient Tumors Global annual market potential 1. Unique Mechanism of Action: Including: • Synthetic lethality LP-184 • Pancreatic Cancer • Overexpre
Slide 13: LP-184 Clinical Trial Updates and Design of Phase 1A Trial
LP-184 Clinical Trial Updates and Design of Phase 1A Trial Dose Level 1 LP-184 Phase 1A Clinical Trial Updates & Design (n=1) • Anticipated Phase 1A Clinical Trial Dates Dose Level 2 Accelerated • IND application submission – Mid-May 2023 (n=1) Cohorts • Study-start up – Q2 2023 • 1st patient dosed
Slide 14: LP-284 Developed from RADR Insights to Late-Stage IND Enabling Studies
LP-284 was Developed from RADR® Insights to Late-Stage IND Enabling Studies in Less Than 2 Years for Non-Hodgkin’s Lymphomas LP-284 for non-Hodgkin’s B-cell lymphomas $1.2 billion Mantle Cell Lymphoma U.S. & Europe LP-284 • • Double Hit Lymphoma annual market potential Program Highlights • LP-284 ha
Slide 15: Presented Multiple Posters at the AACR Annual Meeting 2023
Presented Multiple Posters at the AACR Annual Meeting 2023 Posters highlighted RADR® advancements for patient response prediction and LP-184’s synthetic lethality MoA LP-184, an acylfulvene class small molecule therapeutic, is synthetically lethal in DNA damage repair deficient cancers Aditya Kulkar
Slide 16: Financial Updates Q1 2023
Financial Updates Q1 2023 Solid financial position and capital efficiency fuel continued growth and give Lantern cash runway into 2025 Summary Results of Operations Balance Sheet Highlights & Summary Three Months Ended March 31, (unaudited) 03/31/2023 12/31/2022 2023 2022 (unaudited) Operating expen
Slide 17: 2023 Objectives
2023 Objectives A Transformational year for Lantern ● Advance enrollment of The Harmonic™ Trial & increase patient/clinician awareness ● Launch clinical trials for LP-184 and LP-284 ● Progress LP-184 (STAR-001) towards Ph. 1 / 2 pediatric clinical trial, including ATRT ● Advance ADC preclinical deve
Slide 18: Nasdaq: LTRN IR Contact
IR Contact: IR@lanternpharma.com 1-972-277-1136 Nasdaq: LTRN www.lanternpharma.com @LanternPharma Sign up for Newsletter www.lanternpharma.com/media/newsletter#subscriptionSec CONNECT WITH US 17